Animal Research and Immunology Core

五大湖区域生物防御和新发传染病中心 (GLRCE) 的使命 动物研究和免疫学核心（ARIC）旨在提供专业的研究服务以支持 开发针对 NIAID A、B 和 C 类药物的疫苗、诊断方法和治疗方法，并 在紧急情况下支持 GLRCE、整理湿实验室基础设施和生物防御 RCE 网络的专业知识。在上一个资助期间，SARC 在以下地点建立了基础设施： 芝加哥大学和霍华德·泰勒·里基茨实验室（位于阿贡国家实验室） 实验室）、最先进的 BSL-2/3 和 ABSL-2/3 研究空间，支持工作和科学培训 根据 NIAID A-C 类药物的标准化、安全实验室实践。 GLRCE ARIC 收购 CDC 注册和认证，以维持蓬勃发展的精选代理计划，该计划已涵盖 几种不同的 A-C 病原体：鼠疫耶尔森氏菌（鼠疫）、炭疽芽孢杆菌（炭疽）、伤寒杆菌（斑疹伤寒）、立氏立氏杆菌（洛基） 山斑热）、R. conori（地中海斑热）和 MRSA（耐药金黄色葡萄球菌）。 ARIC 使用基于网络的门户网站 (www.glrce.org) 进行广告并向用户提供研究服务 在研究界，其中包括动物模型、疫苗和免疫的毒力研究 反应研究、激发实验、免疫反应的表征或 感染、免疫试剂和测定的制备、耐药性和治疗研究、 体外和体内微生物复制的测量以及动物病理学研究。对于接下来的 资助期间，GLRCE ARIC提出提供标准化、高质量的动物模型系统，以 开发和维持有氧生物学系统，开发免疫学测试、试剂和相关物 免疫，并开发和维持小分子抑制剂的抗生素活性体外测试 NIAID A-C 类药物。

The mission of the Great Lakes Regional Center for Biodefense and Emerging Infectious Diseases (GLRCE) Animal Research and Immunology Core (ARIC) is to provide professional research services in support of the development of vaccines, diagnostics and therapeutics against NIAID Category A, B and C agents and to support GLRCE under emergency situations, marshalling wet laboratory infrastructures and biodefense expertise for the RCE network. During the previous funding period, SARC established infrastructures at the University of Chicago and at the Howard Taylor Ricketts Laboratory (located at Argonne National Laboratory), state-of-the-art BSL-2/3 and ABSL-2/3 research space, enabling work and scientific training under standardized, safe laboratory practices on NIAID Category A-C agents. The GLRCE ARIC acquired CDC registration and certification to sustain a flourishing select agent program that already encompasses several different A-C agents: Y. pestis (plague), B. anthracis (anthrax), R. typhi (typhus), R. rickettsii (Rocky Mountain Spotted Fever), R. conori (Mediterranean Spotted Fever), and MRSA (drug resistant S. aureus). ARIC uses a web-based portal (www.glrce.org) to advertise and make research services available to users in the research community, which includes virulence studies in animal models, vaccine and immune responses studies, challenge experiments, characterization of immune responses to immunization or infection, preparation of immunological reagents and assays, drug resistance and therapy studies, measurements of microbial replication in vitro and in vivo, and animal pathology studies. For the next funding period, GLRCE ARIC proposes to provide standardized, high quality animal model systems, to develop and sustain aerobiology systems, to develop immunological tests, reagents and correlates of immunity, and to develop and sustain in vitro testing of small molecule inhibitors for antibiotic activity on NIAID category A-C agents.